Prognostic models can have ‘tremendous impact’ on long-term outcomes in CLL
Friday, November 20, 2015
Richard Furman, M.D., the Morton Coleman, M.D. Distinguished Associate Professor of Medicine and co-chair of the leukemia session at Lymphoma & Myeloma 2015, offers insights into the development of prognostic models that can identify patients likely to develop resistance to B-cell receptor antagonists or develop Richter’s transformation in this video on Healio.com/HemOnc Today.
